COMMUNIQUÉS West-GlobeNewswire
-
Alira Health Opens the Registration for the Third Edition of the Global Payer Forum
29/01/2026 -
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
29/01/2026 -
Vystar Enters Final Testing of Breakthrough Dialysis Water Filtration Technology
29/01/2026 -
PCI Biotech initiates a process to evaluate the opportunity for a structured wind-up process
29/01/2026 -
Elevar Therapeutics Names Dong-Gun Kim CEO as It Focuses on Post-NDA Commercialization Strategy
29/01/2026 -
Gameto Licenses Foundational Meiosis IP from Harvard to Advance Human Ovary-in-a-Dish Platform
29/01/2026 -
JenaValve Appoints John Molyneux to Vice President of Operations
29/01/2026 -
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children
29/01/2026 -
Panakeia publishes landmark clinical validation showing AI can deliver rapid molecular profiling for colorectal cancer
29/01/2026 -
Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
29/01/2026 -
Governor Desantis Appoints Dr. Chadwick Marshall to Serve on Florida Board of Dentistry
29/01/2026 -
QTX-2101 Awarded FDA Fast Track Designation for the Treatment of Acute Promyelocytic Leukemia
29/01/2026 -
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy
29/01/2026 -
INVO Fertility Enters into $7.5 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
29/01/2026 -
Fedora Pharmaceuticals Highlights Efficacy of Novel Antibiotic, FPI-2119, against Antimicrobial-resistant Gram-negative Bacteria at the 2026 IMARI Conference
29/01/2026 -
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
29/01/2026 -
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
29/01/2026 -
SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference
29/01/2026 -
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
29/01/2026
Pages